Gland Pharma Reports ₹184 Crore Net Profit in Q2 FY26; Revenue Up 5.8%

Gland Pharma, a leading contract development and manufacturing organisation (CDMO) and injectables firm, announced its financial results for the quarter ended September 30, 2025, reporting steady growth in revenue and profitability alongside strong R&D investments.

Key Financial Highlights

• Net Profit (PAT): ₹184 crore, up 12.3% YoY from ₹164 crore
• Revenue: ₹1,486.8 crore, up 5.8% YoY from ₹1,405.8 crore
• EBITDA: ₹314 crore, up 5.8% YoY; margin stable at 21.1%
• Half-Year Performance: Revenue up 7%; EBITDA up 21% with margin at 23%
• Adjusted EBITDA: Quarterly up 13% YoY; margin expansion of 150 bps

PAT margin improved by 70 bps YoY for the quarter and ~240 bps for the half-year.

Base Business Performance

For the core Gland business:

• Quarterly Revenue: Up 1% YoY; half-yearly up 2%
• Quarterly EBITDA: Up 3% YoY; half-yearly up 12%, maintaining 35% margins
• Adjusted EBITDA: Quarterly up 9% YoY; half-yearly up 16%
• PAT: Quarterly up 7% YoY; half-yearly up 13%, supported by margin gains

R&D and Product Launches

R&D investments rose to ₹614 million in Q2 FY26, representing 5.8% of revenue, compared to ₹460 million in Q1 FY26. Key developments include:

• Launch of seven new molecules in the U.S., including Daptomycin-RTU, Sumatriptan, and Colistimethate
• Filing of six ANDAs and five approvals, bringing cumulative U.S. filings to 378 (329 approved, 49 pending)
• Expansion of Ready-to-Use (RTU) infusion bag portfolio with 20 products filed and 14 approvals, targeting a $659 million U.S. market opportunity

Strategic Pipeline and GLP-1 Expansion

The complex injectables pipeline remains a growth driver, with six products launched and three awaiting approval. Fifteen products are in co-development partnerships, with commercialisation expected from FY28.

In the GLP-1 segment, Gland launched Liraglutide in Q4 FY25 and is scaling production capacity from ~40 million to 140 million units, while exploring opportunities beyond GLP-1 therapies.

Read More: Pfizer Deal Sparks Pharma Rally.

Conclusion

Gland Pharma delivered Q2 FY26 results with improved profitability, strong R&D investments, and a growing pipeline of complex injectables and GLP-1 products. Strategic launches and capacity expansion position the company for sustained growth in global markets.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.